Pharmacokinetics of heparin. II. Studies of time dependence in rats
- PMID: 458631
Pharmacokinetics of heparin. II. Studies of time dependence in rats
Abstract
The purpose of this investigation was to determine whether the time course of heparin activity (bioassayed heparin concentration) in plasma of rats during and after constant rate i.v. infusion of heparin can be predicted from the pharmacokinetic characteristics of a single i.v. bolus dose of heparin administered to the same animals. Five rats received a rapid i.v. injection of heparin, 320 to 517 U/kg, and on the following day, an i.v. infusion of heparin, 2.7 to 4.0 U/min/kg, for 10 to 11 hr. Heparin activity in plasma at the end of the infusion was about twice as high as predicted on the basis of the total clearance of the bolus dose. Even though the maximum heparin activity immediately after the bolus dose and at the end of the infusion were similar, the biologic half-life of heparin at the end of the infusion was about twice as long as that of the bolus dose. Apparently, the pharmacokinetics of heparin are time dependent. This may explain, at least in part, the clinical observation that heparin infusion rate must often be reduced after the initial days of therapy.
Similar articles
-
Pharmacokinetics of heparin. I. Studies of dose dependence in rats.J Pharmacol Exp Ther. 1979 Aug;210(2):237-42. J Pharmacol Exp Ther. 1979. PMID: 458630 No abstract available.
-
[Pharmacokinetics of an unfractionated heparin (Liquemin) in the dog after intravenous and subcutaneous application based on heparin activity].Dtsch Tierarztl Wochenschr. 1999 Nov;106(11):478-81. Dtsch Tierarztl Wochenschr. 1999. PMID: 10609418 German.
-
Pharmacokinetics of recombinant interleukin 2 in humans.Cancer Res. 1990 Apr 1;50(7):2009-17. Cancer Res. 1990. PMID: 2317789
-
Comparison of the pharmacokinetic parameters of digoxin and SC4453 a digoxin analogue, following a single bolus i.v. dose and following an infusion preceeded by an i.v. loading dose in the guinea-pig.J Pharmacol. 1983 Jan-Mar;14(1):9-17. J Pharmacol. 1983. PMID: 6834854
-
Vascular distribution of intratracheally administered heparin.Ann N Y Acad Sci. 1981;370:650-5. doi: 10.1111/j.1749-6632.1981.tb29771.x. Ann N Y Acad Sci. 1981. PMID: 7023328 Review. No abstract available.
Cited by
-
Ultra-low extracorporeal volume microfluidic leukapheresis is safe and effective in a rat model.Nat Commun. 2025 Feb 24;16(1):1930. doi: 10.1038/s41467-025-57003-5. Nat Commun. 2025. PMID: 39994179 Free PMC article.
-
Delivery of therapeutic levels of heparin and low-molecular-weight heparin through a pulmonary route.Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9867-72. doi: 10.1073/pnas.0402891101. Proc Natl Acad Sci U S A. 2004. PMID: 15226520 Free PMC article.
-
The hemocompatibility of oxidized diamond nanocrystals for biomedical applications.Sci Rep. 2013 Oct 25;3:3044. doi: 10.1038/srep03044. Sci Rep. 2013. PMID: 24157697 Free PMC article.
-
Antibody-modified conduits for highly selective cytokine elimination from blood.JCI Insight. 2018 Jul 12;3(13):e121133. doi: 10.1172/jci.insight.121133. JCI Insight. 2018. PMID: 29997301 Free PMC article.
-
Heparin pharmacokinetics and pharmacodynamics.Clin Pharmacokinet. 1992 May;22(5):359-74. doi: 10.2165/00003088-199222050-00003. Clin Pharmacokinet. 1992. PMID: 1505142 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources